Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 30072

 

Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Advertise Contacts Login 
     
ORIGINAL ARTICLE
Year : 2016  |  Volume : 57  |  Issue : 5  |  Page : 253-259

Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study


1 Department of Neurosurgery, University of Wisconsin-Madison, Madison, WI, USA
2 Department of Nephrology, Tabriz University of Medical Sciences, Tabriz, Iran
3 Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Young Researchers Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran
5 Department of Biology, Montgomery College, Rockville, Maryland, USA
6 Department of Internal Medicine, Golestan University of Medical Sciences, Gorgan, Golestan, Iran
7 Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
8 Students' Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
9 Department of Internal Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
10 Department of Ophthalmology, School of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA

Correspondence Address:
Mohammad Naghavi-Behzad
Medical Philosophy and History Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Eastern Azerbaijan
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0300-1652.190600

Rights and Permissions

Background: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied. Materials and Methods: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined. Results: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = −0.484). Conclusions: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6843    
    Printed173    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    
    Cited by others 1    

Recommend this journal